https://openbell.ai/ 2026-09-28T12:48:34.140Z hourly 1.0 https://openbell.ai/support 2026-09-28T12:48:34.140Z monthly 0.7 https://openbell.ai/privacy 2026-09-28T12:48:34.140Z monthly 0.5 https://openbell.ai/terms 2026-09-28T12:48:34.140Z monthly 0.5 https://openbell.ai/feed.json 2026-09-28T12:48:34.140Z hourly 0.8 https://openbell.ai/news/TLS:1790599643354 2026-09-28T12:47:23.354Z daily 0.9 https://cdn.brandfetch.io/TLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Telos Receives $13.7M U.S. Department Of Health And Human Services Contract To Upgrade Its Cyber Governance, Risk And Compliance And Authority To Operate Procedures Telos Corporation (NASDAQ: TLS) has been awarded a $13.7 million contract by the U.S. Department of Health and Human Services (HHS). The contract is aimed at modernizing the agency's cyber governance, risk and compliance (GRC) and Authority to Operate (ATO) processes across its enterprise. https://openbell.ai/news/LFCR:1790599604059 2026-09-28T12:46:44.059Z daily 0.9 https://cdn.brandfetch.io/LFCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lifecore Biomedical To Be Acquired By Webster Equity Partners In Up To $663.7M Transaction; Stockholders May Receive Up To $9.67 Per Common Equivalent In Combined Cash And CVR At Full Performance Milestone Payments Lifecore Biomedical, Inc. has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, contingent on performance milestones. Common stockholders will receive $6.28 per share in cash at closing, representing a 49.5% premium, and may receive up to $9.67 per share including contingent value rights (CVRs) based on future performance. The transaction is expected to close by the end of Q4 2026, pending stockholder and regulatory approvals. Lifecore's stock will be delisted from Nasdaq following the acquisition. https://openbell.ai/news/DXCM:1790599596905 2026-09-28T12:46:36.905Z daily 0.9 https://cdn.brandfetch.io/DXCM/w/400/h/400?c=1idopYfmtR7ZKg8QMud The Insider Report: The Leaders Have Taken Off Dexcom, Inc. (DXCM) reported $1.31 billion in revenue and $249.1 million in earnings for the last quarter, reflecting a 13% increase in revenue. The company is experiencing growth in its continuous glucose monitoring (CGM) business, with the G7 sensor enhancing customer loyalty and margins. Dexcom has raised its full-year 2026 revenue guidance to $5.18–$5.25 billion and executed approximately $600 million in share repurchases in the second quarter. Analysts have rated the stock as a 'Buy' with a target price of $135.00-$140.00. https://openbell.ai/news/AIR:1790599593053 2026-09-28T12:46:33.053Z daily 0.9 https://cdn.brandfetch.io/AIR/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Reiterates Outperform on AAR, Maintains $145 Price Target RBC Capital analyst Ken Herbert has reiterated an 'Outperform' rating on AAR (NYSE: AIR) and maintained a price target of $145 for the stock. This endorsement reflects confidence in AAR's performance in the market. https://openbell.ai/news/SOAR:1790599559354 2026-09-28T12:45:59.354Z daily 0.9 https://cdn.brandfetch.io/SOAR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Volato Group shares are trading higher after the company announced its Alignment Engine subsidiary has entered into two four-year, take-or-pay orders. openbell Financial News https://openbell.ai/news/NNVC:1790599557453 2026-09-28T12:45:57.453Z daily 0.9 https://cdn.brandfetch.io/NNVC/w/400/h/400?c=1idopYfmtR7ZKg8QMud NanoViricides Announces Enrollment And Dosing Begins In Phase 2 Trial Of Oral NV-387 For Ebola In Congo openbell Financial News https://openbell.ai/news/NIO:1790599478255 2026-09-28T12:44:38.255Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Shanghai-china-november-13th-2021-Large-.jpg?width=250&height=187 NIO Secures Geely Capital for Battery Swapping While Retaining Majority Control NIO Inc. has entered a strategic battery-swapping and charging transaction with Zhejiang Geely Holding Group, which will see Geely acquire a 30% stake in NIO Power, valuing it at approximately 16 billion yuan (~$2.38 billion). NIO China will maintain a controlling 63.6% stake post-transaction, and Geely's stake could increase to 34% if certain milestones are met. Additionally, NIO will acquire a 10% stake in Geely's battery-charging subsidiary, Zhejiang Haohan Energy Technology, as both companies aim to expand their energy cooperation. https://openbell.ai/news/MDB:1790599454710 2026-09-28T12:44:14.710Z daily 0.9 https://cdn.brandfetch.io/MDB/w/400/h/400?c=1idopYfmtR7ZKg8QMud MongoDB Affirms FY2027 Adj EPS Guidance of $6.39-$6.58 vs $6.13 Est; Affirms FY2027 Sales Guidance of $2.990B-$3.030B vs $2.954B Est MongoDB (NASDAQ: MDB) has reaffirmed its fiscal year 2027 adjusted earnings per share (EPS) guidance, projecting a range of $6.39 to $6.58, which exceeds the analyst estimate of $6.13. The company also confirmed its sales outlook for FY2027, expecting revenues between $2.990 billion and $3.030 billion, surpassing the estimated $2.954 billion. https://openbell.ai/news/MDB:1790599432644 2026-09-28T12:43:52.644Z daily 0.9 https://cdn.brandfetch.io/MDB/w/400/h/400?c=1idopYfmtR7ZKg8QMud MongoDB Affirms Q3 Adj EPS Guidance of $1.57-$1.61 vs $1.54 Est; Affirms Q3 Sales Guidance of $756.000M-$761.000M vs $745.384M Est MongoDB (NASDAQ: MDB) has reaffirmed its Q3 adjusted EPS guidance in the range of $1.57 to $1.61, surpassing the analyst estimate of $1.54. Additionally, the company confirmed its Q3 sales outlook between $756 million and $761 million, which exceeds the estimated $745.384 million. https://openbell.ai/news/MU:1790599315948 2026-09-28T12:41:55.948Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wedbush Reiterates Outperform on Micron Technology, Maintains $1400 Price Target Wedbush analyst Matt Bryson has reiterated an 'Outperform' rating on Micron Technology (NASDAQ: MU) and has maintained a price target of $1400 for the stock. This endorsement suggests confidence in the company's performance and potential growth in the market. https://openbell.ai/news/NHP:1790599251923 2026-09-28T12:40:51.923Z daily 0.9 https://cdn.brandfetch.io/NHP/w/400/h/400?c=1idopYfmtR7ZKg8QMud National Healthcare Properties shares are trading higher after the company announced it will sell 40 outpatient medical facilities. openbell Financial News https://openbell.ai/news/META:1790599250974 2026-09-28T12:40:50.974Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Meta Platforms Rolls Out Meta Enterprise Platform; Appoints Chirantan Desai As Chief Enterprise Platform Officer Meta Platforms has launched the Meta Enterprise Platform aimed at enhancing business solutions. The company has appointed Chirantan Desai as the Chief Enterprise Platform Officer to lead this initiative. This strategic move is part of Meta's efforts to expand its offerings in the enterprise sector. https://openbell.ai/news/ZS:1790599215667 2026-09-28T12:40:15.667Z daily 0.9 https://cdn.brandfetch.io/ZS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wedbush Reiterates Outperform on Zscaler, Maintains $215 Price Target Wedbush analyst Steven Wahrhaftig has reiterated an 'Outperform' rating on Zscaler (NASDAQ: ZS) and maintained a price target of $215 for the company's stock. No additional financial figures or strategic changes were mentioned in the article. https://openbell.ai/news/GRAL:1790599214965 2026-09-28T12:40:14.965Z daily 0.9 https://cdn.brandfetch.io/GRAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $150 Canaccord Genuity analyst Kyle Mikson has maintained a Buy rating on GRAIL (NASDAQ: GRAL) and raised the price target from $80 to $150. This adjustment reflects a positive outlook for the company's performance. https://openbell.ai/news/LFCR:1790599200828 2026-09-28T12:40:00.828Z daily 0.9 https://cdn.brandfetch.io/LFCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halted at 8:40:00 a.m. ET - Trading Halt: Halt News Pending openbell Financial News https://openbell.ai/news/CTVA:1790599159830 2026-09-28T12:39:19.830Z daily 0.9 https://cdn.brandfetch.io/CTVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud FTC And States Attorneys General Announce Settlement With Corteva Barring Pesticide Loyalty Programs For 10 Years, Corteva To Pay States $35M The Federal Trade Commission (FTC) and several state attorneys general have reached a settlement with Corteva, which prohibits the company from implementing pesticide loyalty programs for the next 10 years. As part of the settlement, Corteva will pay $35 million to the states. This agreement aims to protect farmers by promoting lower pesticide prices and addresses antitrust concerns related to Corteva's business practices. https://openbell.ai/news/APLD:1790599112256 2026-09-28T12:38:32.256Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Applied-Digital-Corporation.jpg?width=250&height=187 Applied Digital's Contracted Backlog Hit $31 Billion — Here's the Bar for Oct. 8 Applied Digital Corporation (NASDAQ: APLD) has a contracted backlog of $31 billion, with potential revenue of up to $73 billion including renewal options. The company is set to report its fiscal Q1 2027 earnings on October 8, with analysts predicting a loss of 30 cents per share and revenue of $134.86 million. Currently, APLD shares are trading 1.60% lower at $25.83, and the stock carries a Buy rating with an average price target of $61.65. https://openbell.ai/news/MIRM:1790599105850 2026-09-28T12:38:25.850Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/FDA-Warns-About-Salmonella-Risks.jpg?width=250&height=187 Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment The FDA has approved Atebrioz (zilurgisertib) tablets for treating fibrodysplasia ossificans progressiva (FOP), a condition characterized by abnormal bone formation. Developed by Incyte and licensed to Mirum Pharmaceuticals, the drug showed a mean decrease of 3.2 cubic centimeters in new HO lesion volume over 24 weeks in clinical trials. Following the approval, Incyte received a Rare Pediatric Disease Priority Review Voucher, and the European Medicines Agency is currently reviewing a marketing authorization application for the drug. In premarket trading, Mirum's shares rose 2.00% to $91.49, while Incyte's shares remained unchanged at $123.89. https://openbell.ai/news/SRFM:1790599105635 2026-09-28T12:38:25.635Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Surf-Air-Mobility.jpg?width=250&height=187 Why Is Surf Air Mobility Stock Gaining Monday? Surf Air Mobility Inc. (NYSE: SRFM) stock rose 9.01% to $1.21 in premarket trading after the company announced its participation in the FAA's SMART program for modernizing U.S. airspace management. This initiative involves a memorandum of agreement where Surf Air will provide operational data and feedback, leveraging its experience from operating Southern Airways and Mokulele Airlines, as well as its AI-enabled platform SurfOS. Analysts have a Buy consensus rating for Surf Air, with an average price forecast of $3, while Canaccord Genuity recently maintained a Hold rating with a price target of $1. https://openbell.ai/news/NEM:1790598995732 2026-09-28T12:36:35.732Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Image-Of-Gold-Bullion-And-Gold-Coins.jpg?width=250&height=187 Why Are Precious Metal Stocks Falling Today? Newmont Corporation (NYSE: NEM) and Barrick Mining Corporation (NYSE: B) experienced declines in premarket trading, with Newmont falling 4.46% to $116.02 and Barrick down 4.29% to $41.04, as gold prices dropped to their lowest in over seven weeks, falling below $4,200 an ounce. This decline is attributed to rising oil prices, which are raising inflation concerns and increasing expectations for further U.S. interest rate hikes, with a 70.3% chance of a rate hike in October. Additionally, spot silver fell 4.8% to $61.17 per ounce, reflecting broader weakness in precious metal markets. https://openbell.ai/news/LXRX:1790598889031 2026-09-28T12:34:49.031Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Crypto-Trader-Investor-Broker-Using-Smar.jpg?width=250&height=187 This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Cantor Fitzgerald analyst Steve Seedhouse has initiated coverage on Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) with an Overweight rating and set a price target of $8. The company's shares closed at $1.80 on Friday, indicating significant upside potential according to the analyst. This initiation is part of a broader trend where analysts are adjusting their ratings on various companies. https://openbell.ai/news/PMAX:1790598838167 2026-09-28T12:33:58.167Z daily 0.9 https://cdn.brandfetch.io/PMAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Powell Max Acquires Minority Stake In Remington Firearms Parent Blackrod Holdings Via Share Exchange Agreement, With Plans To Buy Out Remaining Ownership Interests In Blackrod; Terms Not Disclosed Powell Max (PMAX) has acquired a minority stake in Blackrod Holdings, the parent company of Remington Firearms, through a share exchange agreement. This move is part of PMAX's strategy to expand into new markets, with plans to negotiate a definitive agreement for acquiring the remaining ownership interests in Blackrod. The agreement includes an exclusivity period during which Blackrod cannot solicit competing offers. Specific financial terms of the deal have not been disclosed. https://openbell.ai/news/ONDS:1790598818245 2026-09-28T12:33:38.245Z daily 0.9 https://cdn.brandfetch.io/ONDS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ondas’ Subsidiary Cyberhawk Secures New 3-Yr Agreement, With Option To Extend For Further Two Years, With SSE Plc's Economically-Regulated Networks Businesses For Provision Of Specialist Drone Inspection And Surveying Services Ondas Inc.'s subsidiary Cyberhawk has secured a new three-year agreement, extendable by two years, with SSE plc's regulated networks for specialist drone inspection and surveying services across its UK electricity networks. This agreement also expands Cyberhawk's scope to include offshore wind turbine inspections, integrating it into SSE's offshore renewable generation assets. This marks the third consecutive long-term award in a partnership that has lasted over ten years, alongside a renewed multi-year iHawk™ as a Service agreement. https://openbell.ai/news/BMNR:1790598778861 2026-09-28T12:32:58.861Z daily 0.9 https://cdn.brandfetch.io/BMNR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bitmine Says It Holds 6,001,302 ETH After Buying 17,362 In Past Week; Total Holdings At $17.2B openbell Financial News https://openbell.ai/news/MITQ:1790598774464 2026-09-28T12:32:54.464Z daily 0.9 https://cdn.brandfetch.io/MITQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Moving iMage Technologies Q4 EPS $(0.03) Down From $(0.02) YoY, Sales $4.545M Down From $5.883M YoY Moving iMage Technologies (AMEX: MITQ) reported a Q4 loss of $(0.03) per share, a 50% increase in losses compared to $(0.02) per share in the same quarter last year. The company's sales totaled $4.545 million, reflecting a 22.74% decline from $5.883 million in the previous year. https://openbell.ai/news/T:1790598697639 2026-09-28T12:31:37.639Z daily 0.9 https://cdn.brandfetch.io/T/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Overweight on AT&T, Raises Price Target to $28 Morgan Stanley analyst Simon Flannery has maintained an Overweight rating on AT&T (NYSE: T) and raised the price target from $27 to $28. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/DLHC:1790598694115 2026-09-28T12:31:34.115Z daily 0.9 https://cdn.brandfetch.io/DLHC/w/400/h/400?c=1idopYfmtR7ZKg8QMud DLH Holdings Awarded Task Order Valued At Up To $19.1M To Provide Risk Management Framework And Cybersecurity Operations Support Services To NIH Center For Information Technology DLH Holdings Corp. has been awarded a task order valued at up to $19.1 million to provide risk management framework and cybersecurity operations support services to the NIH Center for Information Technology. This contract, which represents new work for DLH, spans a three-year period and includes various cybersecurity services aimed at enhancing NIH's IT infrastructure. The services will support federal cybersecurity compliance and advance NIH's priorities in areas such as cloud modernization and the use of artificial intelligence. https://openbell.ai/news/SLXN:1790598684769 2026-09-28T12:31:24.769Z daily 0.9 https://cdn.brandfetch.io/SLXN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Silexion Therapeutics Says Preclinical Study Shows SIL204 Uses Natural Blood Lipids To Enter Cancer Cells, Silence KRAS openbell Financial News https://openbell.ai/news/BRX:1790598662375 2026-09-28T12:31:02.375Z daily 0.9 https://cdn.brandfetch.io/BRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Brixmor Property Group shares are trading higher after the company announced it and Everview Partners will acquire Slate Grocery REIT. openbell Financial News https://openbell.ai/news/DIS:1790598438799 2026-09-28T12:27:18.799Z daily 0.9 https://cdn.brandfetch.io/DIS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Reiterates Buy on Walt Disney, Maintains $120 Price Target Guggenheim analyst Michael Morris has reiterated a Buy rating on Walt Disney (NYSE: DIS) and maintained a price target of $120 for the stock. This endorsement suggests confidence in Disney's future performance in the market. https://openbell.ai/news/SG:1790598397372 2026-09-28T12:26:37.372Z daily 0.9 https://cdn.brandfetch.io/SG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wells Fargo Upgrades Sweetgreen to Overweight, Raises Price Target to $11 Wells Fargo analyst Anthony Trainor has upgraded Sweetgreen (NYSE: SG) from Equal-Weight to Overweight. The price target for Sweetgreen has been raised from $6 to $11. https://openbell.ai/news/RBLX:1790598380336 2026-09-28T12:26:20.336Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Roblox-At-Notebook-Screen--Sao-Paulo--Br.jpg?width=250&height=187 Jefferies Downgrades Roblox, Sees Bookings Growth Well Below Wall Street, Stock Falls Roblox Corporation (NYSE: RBLX) shares fell 4.69% to $44.26 after Jefferies downgraded the stock from Hold to Underperform, maintaining a price target of $38, indicating an 18% downside. Jefferies forecasts only 5% bookings growth for fiscal 2027, significantly below Wall Street's estimate of 13%, and has reduced its own bookings estimate by 6% and EBITDA estimate by 21%. The firm expressed concerns over Roblox's need for sustained high investment levels amid slowing growth, drawing parallels to Meta's financial challenges between 2017 and 2019. https://openbell.ai/news/NVDA:1790598333041 2026-09-28T12:25:33.041Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Nvidia.jpg?width=250&height=187 NVIDIA Flexes Its Cash Muscle With Record $150 Billion Buyback Increase NVIDIA Corp. (NASDAQ: NVDA) announced a record increase of $150 billion to its share repurchase program, raising the total authorization to $235 billion, which is expected to be completed by fiscal 2028. This decision reflects management's confidence in the company's cash generation and long-term AI opportunities. Additionally, NVIDIA launched its Open Agent Safety Platform to enhance AI agent security, with over 100 organizations collaborating on the technology. The stock rose nearly 2% in premarket trading, despite a broader market decline. https://openbell.ai/news/KRSA:1790598321496 2026-09-28T12:25:21.496Z daily 0.9 https://cdn.brandfetch.io/KRSA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70 Guggenheim analyst Yatin Suneja has initiated coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating. The firm has set a price target of $70 for the stock. https://openbell.ai/news/BEAG:1790598232046 2026-09-28T12:23:52.046Z daily 0.9 https://cdn.brandfetch.io/BEAG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bold Eagle Acquisition Announces Deal To Take Cyber Intelligence Firm REDLattice Public At $1.25B Enterprise Value openbell Financial News https://openbell.ai/news/FSLR:1790598174235 2026-09-28T12:22:54.235Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Analysts-Debate-Depreciation-Impact.jpg?width=250&height=187 This First Solar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday Keybanc analyst Sophie Karp upgraded First Solar Inc (NASDAQ:FSLR) from Underweight to Sector Weight, with the stock closing at $177.71 on Friday. This upgrade is part of a broader trend where analysts are adjusting their ratings on various companies, including Royal Caribbean and Park Hotels. The article highlights significant upgrades and price targets set by analysts for multiple stocks. https://openbell.ai/news/DARE:1790598069360 2026-09-28T12:21:09.360Z daily 0.9 https://cdn.brandfetch.io/DARE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies Daré Bioscience, Inc. has been granted U.S. Patent No. 12,678,439 for its pharmaceutical compositions that utilize lopinavir and ritonavir for topical treatment of HPV-related cervical pathologies. This patent aims to enhance women's health solutions by providing a new therapeutic option for cervical disorders. https://openbell.ai/news/HUT:1790598012563 2026-09-28T12:20:12.563Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Stock-chartbenzingaai2023-stock-market-c.png?width=250&height=187 Hut 8 Trending as It Adds $1 Billion in Non-Dilutive Bank Liquidity Hut 8 Corp. (NASDAQ: HUT) has closed a $1.07 billion four-year senior secured revolving credit facility, enhancing its liquidity as it aims for an investment-grade corporate profile. This facility includes a $1.07 billion letter-of-credit sublimit to support site development and reduce cash collateral needs. Despite this positive development, Hut 8's stock is currently down 1.36%, trading at $95.50. https://openbell.ai/news/OKTA:1790598011027 2026-09-28T12:20:11.027Z daily 0.9 https://cdn.brandfetch.io/OKTA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Citizens Maintains Market Outperform on Okta, Raises Price Target to $225 Citizens analyst Rustam Kanga has maintained a Market Outperform rating on Okta (NASDAQ: OKTA) and raised the price target from $180 to $225. This adjustment reflects a positive outlook on the company's performance in the market. https://openbell.ai/news/FXI:1790597829955 2026-09-28T12:17:09.955Z daily 0.9 https://cdn.brandfetch.io/FXI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported September 27, USTR Greer Announces U.S. And China Each Recommended $30B In Non-Sensitive Goods That May Benefit From More Favorable Tariff Treatment Under Joint Board Of Trade Ambassador Jamieson Greer announced that the U.S. and China have each recommended $30 billion in non-sensitive goods that may receive more favorable tariff treatment under the U.S.-China Board of Trade. This initiative, established during President Trump's visit to Beijing, aims to improve market access for approximately 30% of U.S. exports to China, including agricultural products and medical devices. The Trump Administration emphasizes its commitment to fair trade practices and compliance with agreements on agricultural and energy purchases. https://openbell.ai/news/TOYO:1790597798779 2026-09-28T12:16:38.779Z daily 0.9 https://cdn.brandfetch.io/TOYO/w/400/h/400?c=1idopYfmtR7ZKg8QMud TOYO Announces About $240M In Binding Solar Module Supply Contracts With Unnamed U.S. Customers, Deliveries Through H1 2027 openbell Financial News https://openbell.ai/news/TOYO:1790597504720 2026-09-28T12:11:44.720Z daily 0.9 https://cdn.brandfetch.io/TOYO/w/400/h/400?c=1idopYfmtR7ZKg8QMud TOYO Sees Meaningful Uncertainty Regarding Its H2 2026 Financial Results; Declines To Provide Quarterly Guidance Or Specific Guidance On Revenue, Net Income Or Other Financial Measures; Expects Positive EBITDA In H2 2026 TOYO has expressed significant uncertainty regarding its financial results for the second half of 2026 due to ongoing U.S. trade and regulatory challenges, including investigations by U.S. Customs and Border Protection. The company has opted not to provide quarterly guidance or specific forecasts for revenue or net income at this time. However, TOYO anticipates achieving positive EBITDA in H2 2026 and plans to update the market as more clarity on regulatory matters develops. https://openbell.ai/news/RNAZ:1790597482900 2026-09-28T12:11:22.900Z daily 0.9 https://cdn.brandfetch.io/RNAZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid Tumors TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced updated clinical data from its Phase 1a trial of TTX-MC138, showing a 71.4% stable disease rate among 14 efficacy-evaluable patients with advanced solid tumors. The disease control rate was 57.1% at three months and 35.7% at six months, with three patients remaining progression-free at one year. The study met its primary endpoint with no dose-limiting toxicities reported across evaluated dose levels, indicating a favorable tolerability profile for the treatment. https://openbell.ai/news/TRLV:1790597475400 2026-09-28T12:11:15.400Z daily 0.9 https://cdn.brandfetch.io/TRLV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trulieve Enters Exclusive Master Licensing Agreement With Connected To Produce And Sell Alien Labs And Connected Branded Cannabis Products In FL And TX openbell Financial News https://openbell.ai/news/TXG:1790597443775 2026-09-28T12:10:43.775Z daily 0.9 https://cdn.brandfetch.io/TXG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110 Argus Research has initiated coverage on 10x Genomics (NASDAQ: TXG) with a Buy rating. The firm has set a price target of $110 for the company's stock. https://openbell.ai/news/FRSX:1790597419727 2026-09-28T12:10:19.727Z daily 0.9 https://cdn.brandfetch.io/FRSX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Foresight Autonomous Announces Non-Binding Term Sheet To Acquire 50.01% Stake In Unnamed Polish Data Center Developer openbell Financial News https://openbell.ai/news/ARAY:1790597399587 2026-09-28T12:09:59.587Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/28/Investors-Show-Virtual-Screen-Stock-Mark.jpg?width=250&height=187 Why Is Accuray Stock Gaining Monday? Accuray Inc. (NASDAQ: ARAY) saw its stock rise 42.07% to $0.3056 in premarket trading following the announcement of a collaboration with Samsung NeuroLogica to enhance volumetric imaging for its CyberKnife system. The partnership aims to integrate Samsung's imaging technology with Accuray's robotic radiosurgery capabilities, with the Royal Marsden NHS Foundation Trust participating as the first center. In its latest earnings report, Accuray posted a loss of 2 cents per share on revenue of $100.9 million, which missed estimates, while service revenue increased by 6%. https://openbell.ai/news/OGN:1790597387982 2026-09-28T12:09:47.982Z daily 0.9 https://cdn.brandfetch.io/OGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis Organon Canada has announced the approval and availability of NDUVRA® (tapinarof cream), 1%, for the treatment of moderate to severe atopic dermatitis in adults and children aged 2 years and older. This new product expands the company's portfolio in dermatological treatments. https://openbell.ai/news/MRK:1790597375797 2026-09-28T12:09:35.797Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Merck's CAPVAXIVE Added To Ontario's Publicly Funded Adult Immunization Program Merck (NYSE: MRK) announced that Ontario has added its CAPVAXIVE® vaccine to the publicly funded adult immunization program, enhancing access for eligible older adults. CAPVAXIVE® is designed to prevent invasive pneumococcal disease (IPD) in adults aged 18 and older. Surveillance data from 2019 to 2023 indicates that the serotypes included in CAPVAXIVE® accounted for approximately 65% of IPD cases in adults aged 18–49, 74% in those aged 50–64, and 80% in adults aged 65 and older. https://openbell.ai/news/LNSR:1790597346433 2026-09-28T12:09:06.433Z daily 0.9 https://cdn.brandfetch.io/LNSR/w/400/h/400?c=1idopYfmtR7ZKg8QMud LUCID CAPITAL MARKETS Initiates Coverage On LENSAR with Buy Rating, Announces Price Target of $11 LUCID CAPITAL MARKETS has initiated coverage on LENSAR (NASDAQ: LNSR) with a Buy rating. The firm has set a price target of $11 for the stock.